From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress
https://www.nature.com/articles/s41392-023-01637-8
Paxalisib (GDC-0084) is a brain-penetrant PI3K/mTOR inhibitor that potently inhibits AKT phosphorylation and reduces orthotopic tumour growth in vivo.285,286 Paxalisib is currently in phase I/II clinical trials for both newly diagnosed and progressive/recurrent glioblastoma in adults (NCT03522298, NCT01547546) and children (NCT05009992) with encouraging preliminary results.
- Forums
- ASX - By Stock
- Unravelling glioblastoma’s secrets and harnessing two decades of progress
From signalling pathways to targeted therapies: unravelling...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online